Do analysts rate PAHC or ELYM?

Phibro Animal Health presently has a consensus target price of $38.80, suggesting a potential upside of 23.06%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate MAZE or ELYM?

Maze Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 174.43%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Maze Therapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MAZE or ELYM more profitable?

Maze Therapeutics' return on equity of -36.62% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts prefer PGEN or ELYM?

Precigen currently has a consensus price target of $12.50, indicating a potential upside of 180.90%. Given Precigen's stronger consensus rating and higher possible upside, research analysts clearly believe Precigen is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend MRVI or ELYM?

Maravai LifeSciences presently has a consensus price target of $5.50, suggesting a potential upside of 10.44%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ELYM or MLTX?

MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 27.59%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has stronger valuation and earnings, ELYM or MLTX?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is ELYM or MLTX more profitable?

Eliem Therapeutics' return on equity of -47.03% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Eliem Therapeutics (ELYM) Competitors

$11.44 +0.53 (+4.86%)

As of 06/12/2026

Compare

ELYM vs. PAHC, MAZE, PGEN, MRVI, and MLTX

Should you buy Eliem Therapeutics stock or one of its competitors? MarketBeat compares Eliem Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eliem Therapeutics include Phibro Animal Health (PAHC), Maze Therapeutics (MAZE), Precigen (PGEN), Maravai LifeSciences (MRVI), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

How does Eliem Therapeutics compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Phibro Animal Health has a net margin of 6.35% compared to Eliem Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Phibro Animal Health presently has a consensus target price of $38.80, suggesting a potential upside of 23.06%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Phibro Animal Health is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Phibro Animal Health has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market.

Phibro Animal Health has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	0.99	$48.26M	$2.33	13.53
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Phibro Animal Health had 16 more articles in the media than Eliem Therapeutics. MarketBeat recorded 16 mentions for Phibro Animal Health and 0 mentions for Eliem Therapeutics. Phibro Animal Health's average media sentiment score of 0.77 beat Eliem Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Phibro Animal Health	Positive
Eliem Therapeutics	Neutral

Summary

Phibro Animal Health beats Eliem Therapeutics on 15 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Eliem Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	7.95	-$131.12M	-$2.53	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Maze Therapeutics had 6 more articles in the media than Eliem Therapeutics. MarketBeat recorded 6 mentions for Maze Therapeutics and 0 mentions for Eliem Therapeutics. Maze Therapeutics' average media sentiment score of 1.06 beat Eliem Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Maze Therapeutics	Positive
Eliem Therapeutics	Neutral

Maze Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 174.43%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Maze Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Maze Therapeutics has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the broader market.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Maze Therapeutics' return on equity of -36.62% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Summary

Maze Therapeutics beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Precigen?

Precigen (NASDAQ:PGEN) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Precigen currently has a consensus price target of $12.50, indicating a potential upside of 180.90%. Given Precigen's stronger consensus rating and higher possible upside, research analysts clearly believe Precigen is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eliem Therapeutics has lower revenue, but higher earnings than Precigen. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	163.89	-$250.64M	-$1.18	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Precigen has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

Eliem Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Eliem Therapeutics	N/A	-47.03%	-45.97%

33.5% of Precigen shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Precigen had 7 more articles in the media than Eliem Therapeutics. MarketBeat recorded 7 mentions for Precigen and 0 mentions for Eliem Therapeutics. Precigen's average media sentiment score of 0.51 beat Eliem Therapeutics' score of 0.00 indicating that Precigen is being referred to more favorably in the media.

Company	Overall Sentiment
Precigen	Positive
Eliem Therapeutics	Neutral

Summary

Precigen beats Eliem Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Eliem Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Eliem Therapeutics	N/A	-47.03%	-45.97%

In the previous week, Maravai LifeSciences had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Maravai LifeSciences and 0 mentions for Eliem Therapeutics. Maravai LifeSciences' average media sentiment score of 0.64 beat Eliem Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Maravai LifeSciences	Positive
Eliem Therapeutics	Neutral

Eliem Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	6.92	-$130.77M	-$0.71	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Maravai LifeSciences presently has a consensus price target of $5.50, suggesting a potential upside of 10.44%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Maravai LifeSciences has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Summary

Maravai LifeSciences beats Eliem Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 27.59%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Eliem Therapeutics' return on equity of -47.03% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

In the previous week, MoonLake Immunotherapeutics had 8 more articles in the media than Eliem Therapeutics. MarketBeat recorded 8 mentions for MoonLake Immunotherapeutics and 0 mentions for Eliem Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.70 beat Eliem Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
MoonLake Immunotherapeutics	Positive

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Summary

MoonLake Immunotherapeutics beats Eliem Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$340.36M	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	-21.58	1.45	24.00	24.42
Price / Sales	N/A	120.49	514.65	112.54
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	2.93	7.85	10.69	6.82
Net Income	-$35.12M	-$4.88M	$3.57B	$337.56M
7 Day Performance	8.44%	0.64%	0.61%	1.16%
1 Month Performance	0.97%	-0.16%	1.56%	3.16%
1 Year Performance	807.94%	47.51%	25.44%	30.60%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$11.44 +4.9%	N/A	+807.9%	$340.36M	N/A	N/A	9
PAHC Phibro Animal Health	4.8977 of 5 stars	$31.18 -4.5%	$38.80 +24.4%	+31.8%	$1.32B	$1.50B	13.38	2,475	Trending News Analyst Revision
MAZE Maze Therapeutics	3.3772 of 5 stars	$23.66 -1.1%	$66.00 +179.0%	+79.5%	$1.32B	$167.50M	N/A	121	Positive News
PGEN Precigen	3.1261 of 5 stars	$3.89 +4.9%	$12.50 +221.3%	+192.8%	$1.32B	$9.68M	N/A	190	News Coverage Gap Up
MRVI Maravai LifeSciences	2.9034 of 5 stars	$5.08 -0.4%	$5.50 +8.3%	+133.8%	$1.32B	$185.74M	N/A	610

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. PAHC, MAZE, PGEN, MRVI, and MLTX

How does Eliem Therapeutics compare to Phibro Animal Health?

Summary

How does Eliem Therapeutics compare to Maze Therapeutics?

Summary

How does Eliem Therapeutics compare to Precigen?

Summary

How does Eliem Therapeutics compare to Maravai LifeSciences?

Summary

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. PAHC, MAZE, PGEN, MRVI, and MLTX

How does Eliem Therapeutics compare to Phibro Animal Health?

Is PAHC or ELYM more profitable?

Do analysts rate PAHC or ELYM?

Do institutionals & insiders believe in PAHC or ELYM?

Which has more risk and volatility, PAHC or ELYM?

Which has preferable valuation & earnings, PAHC or ELYM?

Does the media refer more to PAHC or ELYM?

Summary

How does Eliem Therapeutics compare to Maze Therapeutics?

Which has better valuation & earnings, MAZE or ELYM?

Does the media refer more to MAZE or ELYM?

Do analysts rate MAZE or ELYM?

Which has more risk & volatility, MAZE or ELYM?

Do institutionals and insiders have more ownership in MAZE or ELYM?

Is MAZE or ELYM more profitable?

Summary

How does Eliem Therapeutics compare to Precigen?

Do analysts prefer PGEN or ELYM?

Which has better earnings & valuation, PGEN or ELYM?

Which has more volatility and risk, PGEN or ELYM?

Is PGEN or ELYM more profitable?

Do institutionals & insiders believe in PGEN or ELYM?

Does the media favor PGEN or ELYM?

Summary

How does Eliem Therapeutics compare to Maravai LifeSciences?

Do institutionals & insiders hold more shares of MRVI or ELYM?

Is MRVI or ELYM more profitable?

Does the media favor MRVI or ELYM?

Which has preferable valuation and earnings, MRVI or ELYM?

Do analysts recommend MRVI or ELYM?

Which has more risk & volatility, MRVI or ELYM?

Summary

How does Eliem Therapeutics compare to MoonLake Immunotherapeutics?

Do analysts prefer ELYM or MLTX?

Which has more risk & volatility, ELYM or MLTX?

Is ELYM or MLTX more profitable?

Does the media prefer ELYM or MLTX?

Do insiders & institutionals hold more shares of ELYM or MLTX?

Which has stronger valuation and earnings, ELYM or MLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools